RMPs Prognostic Implications in Pts with Surgically Treated Colon Cancer
the Cancer Therapy Advisor take:
Radial margin positivity (RMP) was associated with recurrence, risk of death, shorter survival, and high rates of conversion and multivisceral resection in patients with colon cancer, according to an article published online in the journal JAMA Surgery.
The study included 984 patients with surgically treated colon cancer, excluding 47 patients with intramucosal tumors, 24 patients with palliative resections, and 16 patients with non-assessable radial margin status.
Results showed 5.3% (52 out of 984) of patients had RMP, and that these patients had increased rates of multivisceral resection (40.4% vs. 12.8%; relative risk, 3.16; 95% CI: 2.18, 4.58; P<0.001) and conversion (50.0% vs. 13.7%; relative risk, 3.78; 95% CI: 1.56, 9.18; P=0.01).
Furthermore, all patients with RMP had stage 2 cancer or higher (according to American Joint Committee on Cancer). This cohort had increased rates of node positivity (86.5% vs. 38.8%; relative risk, 2.23; 95% CI: 1.95, 2.55;<P<0.001), metastasis (34.6% vs. 6.7%; relative risk, 5.20; 95% CI: 3.34-8.11; P<0.001), extramural vascular invasion (76.9% vs. 28.4%; relative risk, 2.71; 95% CI: 2.26, 3.24; P<0.001), and high-grade tumor (45.1% vs. 18.2%; relative risk, 3.01; 95% CI: 2.44, 3.88; P<0.001).
Patients with RMP and without baseline metastasis had greater rates of metastatic disease in follow-ups (37.5% vs. 12.5%; relative risk, 3.32; 95% CI: 2.79, 3.95; P<0.001), especially metastasis of the peritoneum (18.8% vs. 2.6%; relative risk, 7.24; 95% CI: 2.40, 21.8; P<0.001) and liver (18.8% vs. 6%; relative risk, 3.10; 95% CI: 1.08, 8.92; P=0.04).
The study suggests that a timely identification of RMP in patients through preoperative assessments could lead to adequate surgical preparation and therapeutic measures.
Radial margin positivity associated with recurrence, risk of death, shorter survival in patients with colon cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials